Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 36

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 36
---
 engaged in business development activities to identify and pursue new opportunities for its subsidiaries and investments. This may involve partnering with other companies, acquiring new companies, or licensing new technologies. 7 • Talent management: The holding company must have a strong management team with expertise in biotherapeutics, medical device, diagnostics and bioinformatics, and other relevant disciplines in healthcare, as well as corporate finance and business development. The company must also be able to attract and retain talented executives and scientists to lead and support its subsidiaries and investments. Although the BLAC M&A Committee and the BLAC Board believe that the Business Combination with OSR Holdings presents a unique business combination opportunity and is in the best interests of BLAC and its stockholders, the BLAC M&A Committee did consider certain potentially material negative factors in arriving at that conclusion. These factors are discussed in greater detail in the sections entitled “ The Business Combination — The BLAC M&A Committee’s Reasons for the Approval of the Business Combination” and “ Risk Factors — Risks Related to the Business Combination and Business Combination Agreement.” Q:Will the BLAC M&A Committee of the BLAC Board obtain a third -party valuation or fairness opinion in determining whether or not to recommend that the BLAC Board approve the Business Combination? A:Yes. In approving the Business Combination Agreement, the BLAC M&A Committee noted that the closing of the transaction is conditioned on the receipt of a fairness opinion, in form and substance acceptable to the BLAC M&A Committee, concluding that the Business Combination is fair, from a financial point of view, to BLAC stockholders as required by the Current Charter. The BLAC M&A Committee initially engaged a financial advisor based in Switzerland to render the fairness opinion. This decision was made at the time that it was anticipated that OSR Holdings would acquire Landmark Bio Ventures AG (“LBV”), and the resulting company would be more heavily oriented in Europe. However, when OSR Holdings and LBV terminated their agreement, the BLAC M&A Committee determined that it would be more appropriate to engage a financial advisor in Korea because OSR Holdings’ operations would be more heavily weighted toward that geography. In April 2024, the BLAC M&A Committee retained Choloc Asset Investment Advisory Co., Ltd., a financial advisory firm based in Seoul, Korea (“Choloc”), to evaluate the fairness, from a financial point of view, of the Business Combination to the BLAC stockholders. On June 23, 2024, Choloc presented the BLAC M&A Committee a